Literature DB >> 34334919

Overt hematochezia : A rare gastrointestinal presentation in patients with corona virus disease 2019.

Mohammad Darvishi1, Hamze Shahali2.   

Abstract

World health care systems are affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and its associated disease, coronavirus disease 2019 (COVID-19). This new human pathogen mostly affects the respiratory system, but various extrapulmonary pathologies have been reported in the literature. It seems that the gastrointestinal system is one of the target organs for SARS-CoV- 2. Diarrhea as a long-term bowel symptom is not rare, although its occurrence is not as high as that of fever and cough.
© 2021 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.

Entities:  

Keywords:  CO-RADS SCORE; COVID-19; Dysentery; Hematochezia; SARS-CoV-2

Year:  2021        PMID: 34334919      PMCID: PMC8313023          DOI: 10.1016/j.mjafi.2021.04.004

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


Introduction

Coronavirus disease 2019 (COVID-19), which is caused by an RNA beta coronavirus (SARS-CoV-2), is a new human pathogen that first started in Asia and rapidly became a pandemic. Currently, the world health care systems have been plagued by a rapidly transmitted virus with no specific treatment. It mostly affects the respiratory system, ranging from mild flu-like symptoms to severe acute respiratory syndrome (SARS). However, extra respiratory multisystemic involvement (such as neurologic, hematologic, cardiac, and gastrointestinal) has also been reported.1, 2, 3, 4, 5 Efficient personnel is the most important asset of the armed forces. Training experienced military pilots require a lot of resources and hence this manpower needs to be conserved well.

Case report

A 41-year-old male military F-4 pilot who had flu-like syndrome for 2 days as referred to the emergency ward with gastrointestinal (GIT) symptoms (nausea, vomiting, abdominal cramps, and diarrhea) of 24 h duration. He denied any tobacco or drug use, high-risk behaviors, or any other medical history. He had close contact with his teammate, who had a positive reverse transcription polymerase chain reaction (RT-PCR) test for SARS-CoV-2. His vital signs included an oral temperature of 38.5°C, blood pressure of 100/55 mm Hg, heart rate of 121 beats per minute, respiratory rate of 25 breaths per minute, and oxygen saturation of 82%. Significant findings of laboratory assessments for COVID-19 are shown in Table 1. Clinical features, computed tomography (CT) scan findings of the chest, and a positive result for nasopharyngeal swabs RT-PCR test for SARS-CoV-2 was evidence FOR recent COVID-19 pneumonia with CO-RADS SCORE 6 (Fig. 1-A). Bronchoscopic bronchoalveolar lavage did not show a cluster of P.carinii cysts or trophozoites on methenamine silver staining. The patient clinical profile and characteristics of diarrhea are summarized in Table 2. He was admitted to the intensive care unit (ICU) and received standard medication and intensive care based on medications and therapeutic interventions (Table 3). Initially, ceftriaxone, metronidazole, and azithromycin were prescribed for him, but with a negative stool culture response, azithromycin and metronidazole were discontinued. After 9 days from the start of the ICU care, his pneumonia was satisfactorily controlled (based on the progressive improvement evident in serial chest CT scans and oxygen saturation of 90%). However, mild bloody and mucoid diarrhea continued. CT scan with intravenous contrast of his abdomen and pelvis showed severe colonic inflammation, which was most pronounced in the ascending, transverse, and descending colon but was also apparent in the sigmoid colon (Fig. 1B). With suspicion of noninfective causes (such as inflammatory bowel disease [IBD]), colonoscopy and biopsy were requested, and only diffused inflammation and patchy erythema of the colonic mucosa were observed with no evidence of pseudomembranous or Cytomegalovirus (CMV) colitis (Fig. 2). Microscopic findings showed infiltration of numerous plasma cells, lymphocytes, interstitial edema, and congestion in the lamina propria indicating viral colitis. Because we did not see morphological features of CMV colitis, we did not request serum CMV IgM and IgG antibodies and CMV DNA test (PCR test; Fig. 3A). Also, his rectal swabs sampling was positive for the RT-PCR test for SARS-CoV-2. With the clinical judgment of possible COVID-19 GIT complication, he was referred to the COVID-19 ward. Ceftriaxone, levofloxacin, chloroquine, favipiravir, methylprednisolone, and N-acetylcysteine were discontinued. After 11 days of admission to the COVID-19 ward, he was discharged with satisfactory clinical condition with the recommendation for 2 weeks of home rest. On follow-up at Aeromedical Center, his general condition was good, but he complained of weakness, occasional abdominal cramps, and some loose stools. He had negative nasopharyngeal and rectal swab and RT-PCR tests for SARS-CoV-2, significant recovery in the control chest CT scan, and oxygen saturation of 93%. The results of renewed stool examination and colonoscopy were normal. Repeat biopsy revealed only a few infiltrations of lymphocytes in the lamina propria (Fig. 3B). Three months later, his symptoms completely disappeared, and with a satisfactory aeromedical examiner report, the Medical Council released him for duties.
Table 1

Significant laboratory results.

Laboratory testsResultsReference range
RT-PCR tests for SARS-CoV-2Rectal swabsPositiveNegative
Nasopharyngeal swabs
HematologyWhite Blood Cell = 11,400/Cumm3500–10,000
Lymphocyte = 7%PMN = 82%
CD4+ T-lymphocyte cell count = 1050/mm3500–1500
Red blood cell = 4.46 Mil/Cumm3.9–5.5
Hemoglobin = 12.8 gr/dL12–16
Hematocrit = 37.9%34.7–46.7
MCV = 85.1 fl81–100
MCH = 28.6 pg27–34
MCHC = 33.6 gr/dL31.5–35.7
RDW = 13.8%11.6–14.4
Band = 3%
Platelet = 251,000/Cumm150,000–450,000
TIBC = 428 g/dL230–440
Ferritin = 100 ng/mL20–250
Iron (Fe) = 95 g/dL40–120
BiochemistryFBS = 75 mg/dL70–99
BUN = 23 mg/dL7–20
Creatinine = 1 mg/dL0.84–1.21
Alkaline phosphatase = 55 U/L35–104
LDH = 246 U/L135–214
AST = 19 IU/L5–32
ALT = 14 IU/L5–33
Bilirubin total = 0.2 mg/dL0.3–1
Bilirubin direct = 0.1 mg/dL0–0.3
Potassium = 3.2 mmol/L3.6–5.2
Sodium = 128 mEq/L135–145
Magnesium = 0.80 mmol/L0.85–1.10
Calcium = 8.4 mg/dL8.6–10.3
PaO2 = 82 mm Hg80–100
Blood culture (in three times)No growthNo growth after 72 h
SerologyCRP = 18.8 mg/LUp to 8
ESR = 15 mm2–20
AFP = 3.1 IU/mL0–4
CEA = 2.2 IU/mLUp to 4.7
Legionella urine antigen was negativeNegative
Negative HIV antibodyNegative
Stool examinationMacroscopicColor = bloody
Consistency = wateryWell formed
PH = 4.855–8
Mucus = presentAbsent
Blood = presentAbsent
MicroscopicEpithelial cells = 3–4/hpf1–2
WBC = 30–40/hpf1–2
RBC = 35–45/hpfAbsent
Negative for Entamoeba histolytica, Giardia, ova, cyst, or parasitesNot found
Stool cultureNegative for Campylobacter, Salmonella, Shigella, Escherichia coli, Yersinia, and Clostridium difficileNo growth after 72 h
Stool calprotectin>1000 μg/g10–59 years: up to 5
Fig. 1

(A) Axial chest CT scans represented COVID-19 pneumonia with CO-RADS SCORE 6. (B) Intravenous contrast-enhanced CT scan of the abdomen and pelvis. Axial and coronal planes showed severe global colonic inflammation with sigmoid colon involvement which characterized by circumferential wall thickening, mural hyper enhancement, mesenteric hyper vascularity, and pericolic fat stranding (arrows).

Table 2

Defecations specification of patient.

DurationFrequencyStool formRelative volume (for each defecation)Abdominal cramps
First day1–2 times a dayWatery100–200 mLNon
Second and third days2–3 times a dayWatery, bloody, and mucoid150–250 mLModerate
Fourth and fifth days1–2 times a dayOvert hematochezia50–100 mLSevere
Fifth to twentieth days1–3 times a daySemi formed, bloody, and mucoid100–200 mLMild
Table 3

Medications and therapeutic interventions.

Antibacterial therapyAntiviral therapyOxygen therapyVentilation supportMechanical ventilationICU careConservative and adjunctive treatments
CeftriaxoneLevofloxacinChloroquineFavipiravirYesReservoir oxygen and non-rebreather face maskNoYesOral and IV rehydrationElectrolytes replacementMethylprednisoloneScopolamine and dimenhydrinateFamotidine and loperamidePromethazine hydrochlorideN-acetylcysteineVitamins C, D, E, and AZinc and selenium
Fig. 2

Diffused inflammation and patchy erythema of the colonic mucosa.

Fig. 3

(A) Microscopic findings showed numerous infiltrating of plasma cells, lymphocytes, interstitial edema, and congestion in the lamina propria indicated viral colitis. (B) Repeat biopsy revealed only a few infiltrations of lymphocytes in the lamina propria.

Significant laboratory results. (A) Axial chest CT scans represented COVID-19 pneumonia with CO-RADS SCORE 6. (B) Intravenous contrast-enhanced CT scan of the abdomen and pelvis. Axial and coronal planes showed severe global colonic inflammation with sigmoid colon involvement which characterized by circumferential wall thickening, mural hyper enhancement, mesenteric hyper vascularity, and pericolic fat stranding (arrows). Defecations specification of patient. Medications and therapeutic interventions. Diffused inflammation and patchy erythema of the colonic mucosa. (A) Microscopic findings showed numerous infiltrating of plasma cells, lymphocytes, interstitial edema, and congestion in the lamina propria indicated viral colitis. (B) Repeat biopsy revealed only a few infiltrations of lymphocytes in the lamina propria.

Discussion

Diarrhea is defined as a condition that the patient having at least three loose, liquid, or watery bowel movements each day. Diarrhea could be classified into acute or chronic and infectious or noninfectious according to its duration and symptoms. Acute diarrhea lasting less than 2 weeks and viral pathogens are the most common causes and are mostly self-limiting. Instead, chronic diarrhea lasting more than 4 weeks is mainly caused by noninfectious reasons (such as malabsorption, IBD, and drugs). Treatments depend on the duration and etiology. Common management for both forms is replacing fluid and electrolytes loss via oral rehydration (with diluted fruit juice, Pedialyte, or Gatorade) or intravenous fluid administration. A low-fiber diet (bananas, toast, oatmeal, white rice, yogurt, and soup) may help make stool firmer. Antidiarrheal therapy (such as antisecretory or antimotility agents) is contraindicated in adults with bloody diarrhea (dysentery) or high fever because they can worsen severe intestinal infections. Orally or intravenously empiric ceftriaxone, azithromycin, and metronidazole in patients with more severe symptoms should not be prescribed before fecal sampling. Although respiratory droplets and aerosols(especially during unprotected close contact) are the main routes of COVID-19 transmission, the fecal-oral routes may also be a potential route. Recent studies reported SARS-COV-2 detection in feces via either rectal swabs or feces sampling. Currently, very limited fecal RT-PCR are performed for COVID-19 only for research purposes. Multiple GIT presentations, such as anorexia, nausea, vomiting, diarrhea, dysentery, hematochezia, bowel cramps, hiccup, belching, and blowing, are well documented in the literature. Dysentery is a possible GIT complication in COVID-19 patients (with or without pneumonia) that may be resistant to common treatments, persist for a long time, and are accompanied by recurrent episodes. Hemorrhagic colitis with diffuse inflammation and patchy erythema of the colonic mucosa in colonoscopy have been reported in concurrent GIT and COVID-19 pulmonary infection. New onset or recurrent IBD may be one of the other GIT complications of COVID-19 infection. However, a definitive IBD diagnosis needs colonoscopy and pathological assessment. From an aeromedical point of view, he will not be allowed to return to flying until he has full recovery with normal tests and a satisfactory report from the aeromedical council. Indeed, his in-flight medical sudden incapacitation risk must be less than1% for rejoining.

Conclusions

For all practical purposes, this case can be considered as COVID-19 with bloody diarrhea. Because of laboratory limitations and the exposure risk for the health care personnel, more evaluation and research should be done in the future on this topic.

Ethics approval and consent to participate

The ethical approval of this study was issued with registration N# 10167138 by the Ethics Committee of the Medical Faculty in Aja University of Medical Sciences.

Disclosure of competing interest

The authors have none to declare.
  6 in total

1.  The convalescent sera option for containing COVID-19.

Authors:  Arturo Casadevall; Liise-Anne Pirofski
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

3.  The occurrence of diarrhea in COVID-19 patients.

Authors:  Xiang-Yu Li; Wei-Jie Dai; Shang-Nong Wu; Xiao-Zhong Yang; Hong-Gang Wang
Journal:  Clin Res Hepatol Gastroenterol       Date:  2020-04-03       Impact factor: 2.947

4.  SARS-CoV-2 Gastrointestinal Infection Causing Hemorrhagic Colitis: Implications for Detection and Transmission of COVID-19 Disease.

Authors:  Alexandre Carvalho; Rana Alqusairi; Anna Adams; Michelle Paul; Neelay Kothari; Stevany Peters; Anthony T DeBenedet
Journal:  Am J Gastroenterol       Date:  2020-06       Impact factor: 10.864

5.  Can COVID-19 present unusual GI symptoms?

Authors:  Ahmad Hormati; Alireza Shahhamzeh; Mahboubeh Afifian; Fatemeh Khodadust; Sajjad Ahmadpour
Journal:  J Microbiol Immunol Infect       Date:  2020-03-21       Impact factor: 4.399

  6 in total
  2 in total

1.  Thalamic hemi-chorea: a rare complication after receiving the adenoviral vector-based COVID-19 vaccine: a case report.

Authors:  Hamze Shahali; Ramin Hamidi Farahani; Ali Asgari; Ebrahim Hazrati
Journal:  Clin Exp Vaccine Res       Date:  2022-05-31

2.  Acute vestibular neuritis: A rare complication after the adenoviral vector-based COVID-19 vaccine.

Authors:  Hamze Shahali; Ramin Hamidi Farahani; Parham Hazrati; Ebrahim Hazrati
Journal:  J Neurovirol       Date:  2022-07-25       Impact factor: 3.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.